Our immune-activating therapies use plasmid DNA (genetically engineered material encoding a human antigen) to develop immunotherapies that activate the body’s own immune system to target specific features of prostate cancer cells.
Combined Cost Of Goods for our immune-activating agents portend favorable reimbursement potential for use in combination with checkpoint inhibitors or with androgen deprivation therapies
Our product candidates are in clinical trials as monotherapy, and as combination therapy with approved agents.
MVI products are readily manufactured, highly stable, and are administered by simple skin injection. We target patients with the highest risk of developing bone or other metastases after their initial therapy as well as patients who have already developed metastatic prostate cancer.